Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the drug resource enhancement against AIDS and malnutrition model: Antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 268-275

  Palombi, Leonardo ^a   Bernava, Giuseppe M ^b   Nucita, Andrea ^d   Giglio, Pietro ^e   Liotta, Giuseppe ^a   Nielsen Saines, Karin ^f   Orlando, Stefano ^b   Mancinelli, Sandro ^a   Buonomo, Ersilia ^a   Scarcella, Paola ^a   Altan, Anna Maria Doro ^a   Guidotti, Gianni ^b   Ceffa, Susanna ^b   Haswell, Jere ^g   Zimba, Ines ^h   Magid, Nurja Abdul ^h   Marazzi, Maria Cristina ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Sant'Egidio Community   (United States)

^c LUMSA UNIVERSITY   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DREAM Program   (Malawi)

^h DREAM Program   (Mozambique)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SEXUAL TRANSMISSION; STOCHASTIC MODEL; SURVIVAL; VIRUS INFECTIVITY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALAWI; MALE; MIDDLE AGED; MODELS, THEORETICAL; MOZAMBIQUE; PREVALENCE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84864140017     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis380     Document Type: Article

References (23)

1. Granich MR, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
2. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 343:921-9. (Pubitemid 30177052)
3. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PloS Med 2010; 5:e11068.
4. Donnel D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretrovirval therapy: a prospective cohort analysis. Lancet 2010; 375:2092-8.
5. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviraltreated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115-22.
6. Lutalo T, Gray RH, Wawer M, et al. Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007; 21:S15-9. (Pubitemid 350158884)
7. Chan KC, Yip B, Hogg RS, Montaner JS, O'Shaughnessy MV. Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States. AIDS 2002; 16:1693-5. (Pubitemid 34921119)
8. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003; 17:711-20. (Pubitemid 36521077)
9. Kretzschmar M, Morris M. Measures of concurrency in networks and the spread of infectious diseases. Math Biosci 1996; 133:165-95.
10. World Health Organization. World Health Statistics 2008. Available at: http://www.who.int/whosis/whostat/2008/en/index.html. Accessed 15 August 2011.
11. World Health Organization. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. November, 2009. http://www.who.int/liv/pub/mtct/advice/en. Accessed 22 July 2011.
12. Badri M, Maartens G, Mandalia S, et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006; 3:e4.
13. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
14. Marazzi MC, Nielsen-Saines K, Buonomo E, et al. Increased infant human immunodeficiency virus-type one-free survival at one year of age in Sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breastfeeding. Ped Infect Dis J 2009; 28:483-7.
15. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288:189-98. (Pubitemid 34755279)
16. Marazzi MC, Liotta G, Nielsen-Saines K, et al. Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life. AIDS 2010; 24:2819-26.
17. Magnano San Lio M, Mancinelli S, Palombi L, et al. The DREAM model's effectiveness in health promotion of AIDS patients in Africa. Health Promot Int 2009; 24:6-15.
18. Schwartländer B, Stover J, Hallett T, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011; 377:2031-41.
19. Palombi L, Marazzi MC, Voetberg A, Magid NA, and the DREAM Program Prevention of Mother-to-Child Transmission Team. Treatment acceleration program and the experience of the DREAM Program in the prevention of mother-to-child transmission of HIV. AIDS 2007; 21:S65-71. (Pubitemid 47051751)
20. Anema A, Au-Yeung CG, Joffres M, et al. Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther 2011; 8:13.
21. Orlando S, Marazzi MC, Mancinelli S, et al. Cost-effectiveness of using HAART in the prevention of mother to child transmission in the DREAM Project Malawi. J AIDS 2010; 55:631-4.
22. Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy in resource-limited settings for the prevention of HIV-1 mother-to-child transmission correlates with favorable pregnancy outcomes. AIDS 2011; 25:1611-8.
23. Liotta G, Mancinelli S, Gennaro E, et al. Is Highly active antiretroviral therapy (HAART) in pregnancy protective against maternal mortality? Results from a large DREAM cohort in Malawi and Mozambique abstract TUAB0201. In: Program and abstracts of the Sixth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention (Rome). Italy, 2011:160.